• 1
    Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in australia: an overview, 2010. canberra: AIHW; 2010. Cancer Series no. 37. Cat no. CAN32
  • 2
    Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007; 177: 437443
  • 3
    Bellmunt J, Orsola A, Maldonado X, Kataja V. Bladder cancer: esmo practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v134136
  • 4
    Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859866
  • 5
    International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 21712177
  • 6
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database of Syst Rev 2004; 1. Art. No.: CD005246
  • 7
    Maase von der H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 46024608
  • 8
    Dash A, Pettus J A IV, Herr HW et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. Cancer 2008; 113: 24712477
  • 9
    Skinner DG, Daniels JR, Russo P et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 459464
  • 10
    Stöckle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995; 153: 4752
  • 11
    Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495499
  • 12
    Cognetti F, Ruggeri EM, Felici A et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an italian, multicenter, randomized phase III trial. Ann Oncol 2012; 23: 695700
  • 13
    Stadler WM, Lerner SP, Groshen S et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011; 29: 34433449
  • 14
    Vale CL, Advanced Bladder Cancer Meta-analysis collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006; 2, CD006018
  • 15
    Au-Yeung GH, Aly A, Bui A, Vermeltfoort CM, Davis ID. Uptake of oncology multidisciplinary meeting recommendations. Med J Aust 2012; 196: 3637
  • 16
    Liew MS, Au-Yeung G, Davis ID. Pathological responses to gemcitabine/platinum-based neoadjuvant chemotherapy for muscle-invasive urothelial cancer. Asia-Pac J Clin Oncol 2012; 8: 101102
  • 17
    Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373383
  • 18
    Edge SB, Compton CC. The american joint committee on cancer: the 7th edition of the ajcc cancer staging manual and the future of tnm. Ann Surg Oncol 2010; 17: 14711474
  • 19
    Matsui Y, Nishiyama H, Watanabe J et al. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in japan. Int J Clin Oncol 2004; 10: 133138
  • 20
    David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the national cancer data base. J Urol 2007; 178: 451454
  • 21
    Raj GV, Karavadia S, Schlomer B et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2010; 117: 276282
  • 22
    Porter MP, Kerrigan MC, Donato BMK, Ramsey SD. Patterns of use of systemic chemotherapy for medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2011; 29: 252258
  • 23
    Wosnitzer MS, Hruby GW, Murphy AM et al. A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer. Cancer 2011; 118: 358364
  • 24
    Booth CM, Siemens DR, Tannock IF, Peng Y, Li G, Mackillop WJ. Adoption of neoadjuvant and adjuvant chemotherapy for bladder cancer: a population-based study. J Clin Oncol 2011; 29 (suppl; abstr 4644)
  • 25
    Feifer AH, Taylor JM, Shouery M et al. Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: phase I. J Clin Oncol 2011; 29 (suppl 7; abstr 240)
  • 26
    Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the national cancer database, 2003 to 2007. J Urol 2011; 185: 7278
  • 27
    Koppie TM, Serio AM, Vickers AJ et al. Age-adjusted charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008; 112: 23842392
  • 28
    Watts KL, Ristau BT, Yamase HT, Taylor JA III. Prognostic implications of lymph node involvement in bladder cancer: are we understaging using current methods? BJU Int 2011; 108: 484492
  • 29
    Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 2000; 163: 16931696
  • 30
    Kibel AS, Dehdashti F, Katz MD et al. Prospective study of [18F] flurodeoxyglucose positron emission tomography/computer tomography for staging of muscle-inavsive bladder carcinoma. J Clin Oncol 2009; 27: 43144320
  • 31
    Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS. Mortality increases when radical cystectomy is delayed more than 12 weeks. Cancer. 2009; 115: 988996
  • 32
    Bellmunt J, Maase von der H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: eortc intergroup study 30987. J Clin Oncol 2012; 30: 11071113
  • 33
    Weight CJ, Garcia JA, Hansel DE et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Cancer 2009; 115: 792799
  • 34
    Ghadjar P, Burkhard FC, Gautschi O, Thalmann GN, Studer UE. Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU Int 2010; 107: 894897
  • 35
    Scosyrev E, Messing EM, van Wijngaarden E et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 2011; 118: 7281
  • 36
    Yeshchina O, Badalato GM, Wosnitzer MS et al. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology 2012; 79: 384390